De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumori…

In order to develop more effective therapeutic vaccines against cancers with high-risk human papillomavirus (HPV) infection, it is crucial to enhance the immunogenicity, eliminate the oncogenicity of oncoproteins, and take a combination of E7- and E6-containing vaccines. It has been shown recently that PE(DIII)-E7-KDEL3 (E7), a fusion protein containing the HPV16 oncoprotein E7 and the translo…